Cargando…

Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS

Aflatoxin B(1) (AFB(1)) is a highly hepatotoxic and carcinogenic mycotoxin produced by Aspergillus species. The compound is mainly metabolized in the liver and its metabolism varies between species. The present study quantified relevant AFB(1)- metabolites formed by mouse, rat, and human primary hep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerdemann, Andrea, Cramer, Benedikt, Degen, Gisela H., Veerkamp, Jannik, Günther, Georgia, Albrecht, Wiebke, Behrens, Matthias, Esselen, Melanie, Ghallab, Ahmed, Hengstler, Jan G., Humpf, Hans-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567917/
https://www.ncbi.nlm.nih.gov/pubmed/37794256
http://dx.doi.org/10.1007/s00204-023-03607-z
_version_ 1785119243239424000
author Gerdemann, Andrea
Cramer, Benedikt
Degen, Gisela H.
Veerkamp, Jannik
Günther, Georgia
Albrecht, Wiebke
Behrens, Matthias
Esselen, Melanie
Ghallab, Ahmed
Hengstler, Jan G.
Humpf, Hans-Ulrich
author_facet Gerdemann, Andrea
Cramer, Benedikt
Degen, Gisela H.
Veerkamp, Jannik
Günther, Georgia
Albrecht, Wiebke
Behrens, Matthias
Esselen, Melanie
Ghallab, Ahmed
Hengstler, Jan G.
Humpf, Hans-Ulrich
author_sort Gerdemann, Andrea
collection PubMed
description Aflatoxin B(1) (AFB(1)) is a highly hepatotoxic and carcinogenic mycotoxin produced by Aspergillus species. The compound is mainly metabolized in the liver and its metabolism varies between species. The present study quantified relevant AFB(1)- metabolites formed by mouse, rat, and human primary hepatocytes after treatment with 1 µM and 10 µM AFB(1). The use of liquid chromatographic separation coupled with tandem mass spectrometric detection enabled the selective and sensitive determination of phase I and phase II metabolites of AFB(1) over incubation times of up to 24 h. The binding of AFB(1) to macromolecules was also considered. The fastest metabolism of AFB(1) was observed in mouse hepatocytes which formed aflatoxin P(1) as a major metabolite and also its glucuronidated form, while AFP(1) occurred only in traces in the other species. Aflatoxin M(1) was formed in all species and was, together with aflatoxin Q(1) and aflatoxicol, the main metabolite in human cells. Effective epoxidation led to high amounts of DNA adducts already 30 min post-treatment, especially in rat hepatocytes. Lower levels of DNA adducts and fast DNA repair were found in mouse hepatocytes. Also, protein adducts arising from reactive intermediates were formed rapidly in all three species. Detoxification via glutathione conjugation and subsequent formation of the N-acetylcysteine derivative appeared to be similar in mice and in rats and strongly differed from human hepatocytes which did not form these metabolites at all. The use of qualitative reference material of a multitude of metabolites and the comparison of hepatocyte metabolism in three species using advanced methods enabled considerations on toxification and detoxification mechanisms of AFB(1). In addition to glutathione conjugation, phase I metabolism is strongly involved in the detoxification of AFB(1). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-023-03607-z.
format Online
Article
Text
id pubmed-10567917
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-105679172023-10-13 Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS Gerdemann, Andrea Cramer, Benedikt Degen, Gisela H. Veerkamp, Jannik Günther, Georgia Albrecht, Wiebke Behrens, Matthias Esselen, Melanie Ghallab, Ahmed Hengstler, Jan G. Humpf, Hans-Ulrich Arch Toxicol Organ Toxicity and Mechanisms Aflatoxin B(1) (AFB(1)) is a highly hepatotoxic and carcinogenic mycotoxin produced by Aspergillus species. The compound is mainly metabolized in the liver and its metabolism varies between species. The present study quantified relevant AFB(1)- metabolites formed by mouse, rat, and human primary hepatocytes after treatment with 1 µM and 10 µM AFB(1). The use of liquid chromatographic separation coupled with tandem mass spectrometric detection enabled the selective and sensitive determination of phase I and phase II metabolites of AFB(1) over incubation times of up to 24 h. The binding of AFB(1) to macromolecules was also considered. The fastest metabolism of AFB(1) was observed in mouse hepatocytes which formed aflatoxin P(1) as a major metabolite and also its glucuronidated form, while AFP(1) occurred only in traces in the other species. Aflatoxin M(1) was formed in all species and was, together with aflatoxin Q(1) and aflatoxicol, the main metabolite in human cells. Effective epoxidation led to high amounts of DNA adducts already 30 min post-treatment, especially in rat hepatocytes. Lower levels of DNA adducts and fast DNA repair were found in mouse hepatocytes. Also, protein adducts arising from reactive intermediates were formed rapidly in all three species. Detoxification via glutathione conjugation and subsequent formation of the N-acetylcysteine derivative appeared to be similar in mice and in rats and strongly differed from human hepatocytes which did not form these metabolites at all. The use of qualitative reference material of a multitude of metabolites and the comparison of hepatocyte metabolism in three species using advanced methods enabled considerations on toxification and detoxification mechanisms of AFB(1). In addition to glutathione conjugation, phase I metabolism is strongly involved in the detoxification of AFB(1). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00204-023-03607-z. Springer Berlin Heidelberg 2023-10-05 2023 /pmc/articles/PMC10567917/ /pubmed/37794256 http://dx.doi.org/10.1007/s00204-023-03607-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Organ Toxicity and Mechanisms
Gerdemann, Andrea
Cramer, Benedikt
Degen, Gisela H.
Veerkamp, Jannik
Günther, Georgia
Albrecht, Wiebke
Behrens, Matthias
Esselen, Melanie
Ghallab, Ahmed
Hengstler, Jan G.
Humpf, Hans-Ulrich
Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS
title Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS
title_full Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS
title_fullStr Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS
title_full_unstemmed Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS
title_short Comparative metabolism of aflatoxin B(1) in mouse, rat and human primary hepatocytes using HPLC–MS/MS
title_sort comparative metabolism of aflatoxin b(1) in mouse, rat and human primary hepatocytes using hplc–ms/ms
topic Organ Toxicity and Mechanisms
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567917/
https://www.ncbi.nlm.nih.gov/pubmed/37794256
http://dx.doi.org/10.1007/s00204-023-03607-z
work_keys_str_mv AT gerdemannandrea comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT cramerbenedikt comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT degengiselah comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT veerkampjannik comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT gunthergeorgia comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT albrechtwiebke comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT behrensmatthias comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT esselenmelanie comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT ghallabahmed comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT hengstlerjang comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms
AT humpfhansulrich comparativemetabolismofaflatoxinb1inmouseratandhumanprimaryhepatocytesusinghplcmsms